Zogenix, Inc. (NASDAQ:ZGNX) – William Blair issued their Q1 2021 earnings estimates for shares of Zogenix in a research report issued to clients and investors on Friday, June 26th. William Blair analyst T. Lugo expects that the company will earn ($0.85) per share for the quarter. William Blair has a “Buy” rating on the stock. William Blair also issued estimates for Zogenix’s Q2 2021 earnings at ($0.67) EPS, Q3 2021 earnings at ($2.99) EPS and Q4 2021 earnings at ($0.37) EPS.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.54. The firm had revenue of $1.25 million during the quarter, compared to analyst estimates of $0.38 million. Zogenix had a negative return on equity of 47.19% and a negative net margin of 8,374.54%. Zogenix’s quarterly revenue was up 124800.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.83) earnings per share.
A number of other brokerages have also issued reports on ZGNX. Piper Sandler lowered their price target on Zogenix from $64.00 to $56.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Citigroup started coverage on Zogenix in a research report on Thursday, March 5th. They issued a “neutral” rating and a $27.00 target price on the stock. BidaskClub downgraded Zogenix from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. Needham & Company LLC cut their target price on Zogenix from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Finally, Northland Securities started coverage on Zogenix in a research report on Friday, June 26th. They issued a “buy” rating and a $65.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zogenix has a consensus rating of “Buy” and an average price target of $54.36.
Shares of NASDAQ ZGNX opened at $26.11 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.39 and a current ratio of 5.39. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -2.77 and a beta of 1.79. The stock has a 50 day moving average price of $28.77 and a 200 day moving average price of $34.20. Zogenix has a 52-week low of $16.65 and a 52-week high of $57.22.
Hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. purchased a new stake in shares of Zogenix during the 4th quarter worth about $66,000. US Bancorp DE boosted its stake in shares of Zogenix by 2,196.6% during the 1st quarter. US Bancorp DE now owns 1,332 shares of the company’s stock worth $32,000 after acquiring an additional 1,274 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Zogenix during the 4th quarter worth about $118,000. Amundi Pioneer Asset Management Inc. purchased a new position in Zogenix in the 1st quarter valued at about $193,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Zogenix by 63.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,691 shares of the company’s stock valued at $91,000 after buying an additional 1,432 shares in the last quarter.
In other news, EVP Ashish M. Sagrolikar bought 1,000 shares of the stock in a transaction dated Friday, May 8th. The shares were acquired at an average cost of $27.61 per share, with a total value of $27,610.00. Following the purchase, the executive vice president now directly owns 5,913 shares in the company, valued at approximately $163,257.93. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 3.50% of the stock is currently owned by corporate insiders.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Recommended Story: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.